Feed MDWD
MD

MediWound Ltd.

MDWD · NASDAQ

$13.40 -0.15% (-$0.02)
1M +1.44%
Market Cap $171.5M
P/E Ratio -
Div. Yield -
ROE 47.24%
Piotroski F-Score Weak
1/9
Valuation
20 /100
Expensive
P/S 14.46x
P/B 4.81x
P/E N/A
Growth
22 /100
Declining
Rev. growth 13.82%
Book val. growth 58.71%
EPS growth N/A
Profitability
4 /100
Weak
Gross margin 15.46%
Net margin 170.10%
Op. margin 267.86%
Quality
2 /100
Poor
ROIC 70.36%
ROE 47.24%
ROA 28.07%
Debt
69 /100
Low
Debt/Equity 0.27x
Current ratio 2.32x
Int. coverage -18.64x
Stability
18 /100
Unstable
Beta 0.14x
Rev. volatility 19.11%
EPS volatility 209.25%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about MDWD
Online

About the company

MediWound Ltd. (MDWD) is a biotechnology company focused on the development of innovative therapeutic products for the treatment of skin injuries, burns, and other dermatological conditions. Their main product is an enzymatic medicinal preparation called NexoBrid®, which is used for the removal of burned tissue and promotes wound healing. MediWound Ltd. is known for its research and development of new treatment methods aimed at improving the treatment of patients with burns and other skin injuries. The company also offers additional therapeutic products and services for the healthcare sector. MediWound Ltd. (MDWD) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on the treatment of skin injuries and burns.

Sector

Healthcare

Industry

Biotechnology

CEO

Ofer Gonen

Employees

121

Headquarters

Yavne

Upcoming events

19 NOV

Earnings

Upcoming earnings report

60d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.